JULIA LAINHART: Open Payments
NPI 1487248506 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$218 in 11 payments from 6 companies in 2025. Trend: 2023 $324 · 2024 $130 · 2025 $218
Food & beverage: $218
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $55 |
| ABBVIE INC. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Alkermes, Inc. | 1 | $29 |
| GlaxoSmithKline, LLC. | 1 | $16 |
Products named: CAPLYTA, Ozempic, REXULTI, VRAYLAR, VIVITROL, QULIPTA, Rybelsus, SHINGRIX.
Industry payments across NE — which companies pay providers there.
